Leica Biosystems introduces the Novocastra HD menu for dermatopathology, the third portfolio of antibodies for IHC in the new Novocastra HD range.
Place: Newcastle-upon-Tyne, UK.
Leica Biosystems introduces the Novocastra HD menu for dermatopathology, the third portfolio of antibodies for IHC in the new Novocastra HD range.
Each antibody has been independently assessed* for performance vs. their competitive offerings in the market, thereby enabling confidence in the interpretation of stained slides. The BOND Ready-to-Use products are optimized to deliver high quality staining on the BOND immunostainer. Products are available in a range of formats to align with customer requirements for efficiency and convenience.
Dr Robb E. Wilentz of Skin and Cancer Associates, Aventura, FL commented, “Leica has a wide variety of reliable antibodies covering the antigens routinely studied in our field of dermatopathology. Together with the BOND immunohistochemistry platform, this enables us to provide our clients with consistent, accurate and timely results. We are happy to have incorporated Leica's systems and dermatology antibodies into our daily routine."
The new Novocastra HD menu for dermatopathology comprises twelve** antibodies and will be available for sale in the USA, Canada and the EU from March 2013. Availabillity in other regions will follow. Full details can be found at www.LeicaBiosystems.com/NovocastraHD.
Many BOND Ready-to-Use antibodies come in two sizes: 7 mL and a new 30 mL size for higher usage requirements. Liquid concentrates are available in an expanded range of sizes from 0.1 mL to 1 mL.
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting.
The company is represented in over 100 countries. It has manufacturing facilities in 6 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at www.LeicaBiosystems.com
For more information contact:
Tim Lyons
Global Marketing Communications Director
Leica Biosystems
1700 Leider Lane
Buffalo Grove, IL
USA
Telephone: + 1 847 405 5455
Mobile: +1 847 5010768
Email: tim.lyons@LeicaBiosystems.com
www.LeicaBiosystems.com
